TAMPER-RESISTANT ORAL PHARMACEUTICAL DOSAGE FORM COMPRISING OPIOID ANTAGONIST AND/OR AVERSIVE AGENT, POLYALKYLENE OXIDE AND ANIONIC POLYMER

• US 20130129826A1
• Filed: 11/15/2012
• Published: 05/23/2013
• Est. Priority Date: 11/17/2011
• Status: Abandoned Application

• Current Assignee: Grunenthal GMBH (Grünenthal Pharma GmbH & Co. KG)
• Original Assignee: Grunenthal GMBH (Grünenthal Pharma GmbH & Co. KG)
• Inventors: GEILER, Anja, BARNSCHEID, Lutz, BARTHOLOMUS, Johannes, SCHWIER, Sebastian
• Application Number:
  US13/677,446
• Publication Number:
  US 20130129826A1
• Time in Patent Office: Days
• US Class Current: 424/486
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/485 Morphinan derivatives, e.g. morphine, codeine
• CPC Class Codes: A61K 47/10 Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• CPC Class Codes: A61K 47/32 Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers , poly(meth)acrylates, or polyvinyl pyrrolidone
• CPC Class Codes: A61K 9/2027 obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
• CPC Class Codes: A61K 9/2031 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
• CPC Class Codes: A61K 9/2054 Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
• CPC Class Codes: A61K 9/2095 Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing mechanical aspects A61J3/00
• CPC Class Codes: A61P 25/04 Centrally acting analgesics, e.g. opioids
• CPC Class Codes: A61P 25/36 Opioid-abuse

Abstract

The invention relates to a pharmaceutical dosage form for oral administration having a breaking strength of at least 300 N and comprising (i) a pharmacologically active ingredient; (ii) an opioid antagonist and/or an aversive agent; (iii) a polyalkylene oxide having an average molecular weight of at least 200,000 g/mol; and (a) further comprising (iv) an anionic polymer; and/or (b) having a storage stability at 40° C. of at least 3 months.

Claims

1. A pharmaceutical dosage form for oral administration having a breaking strength of at least 300 N and comprising (i) a pharmacologically active ingredient;

(ii) an opioid antagonist and/or an aversive agent;

(iii) a polyalkylene oxide having an average molecular weight of at least 200,000 g/mol; and

(a) further comprising (iv) an anionic polymer;

and/or

(b) having a storage stability at 40°

C. of at least 3 months.

2. The pharmaceutical dosage form according to claim 1, wherein the anionic polymer comprises anionic functional groups selected from carboxyl groups, sulfonyl groups, sulfate groups, and phosphoryl groups.

3. The pharmaceutical dosage form according to claim 1, wherein the anionic polymer is derived from a monomer selected from acrylic acid, alkyl acrylates and alkyl alkacrylates, or a combination thereof.

4. The pharmaceutical dosage form according to claim 1, wherein in accordance with Ph. Eur. the in vitro release profile of the pharmacologically active ingredient opioid agonist essentially corresponds to the in vitro release profile of the opioid antagonist and/or the aversive agent.

5. The pharmaceutical dosage form according to claim 1, wherein the pharmacologically active ingredient opioid agonist and the opioid antagonist and/or the aversive agent are homogeneously distributed over the pharmaceutical dosage form or, when the pharmaceutical dosage form comprises a film coating, over the coated core of the pharmaceutical dosage form.

6. The pharmaceutical dosage form according to claim 1, wherein the pharmacologically active ingredient opioid agonist and the opioid antagonist and/or the aversive agent are embedded in a prolonged release matrix comprising the polyalkylene oxide and the anionic polymer.

7. The pharmaceutical dosage form according to claim 1, which is configured for administration once daily or twice daily.

8. The pharmaceutical dosage form according to claim 1, which is monolithic.

9. The pharmaceutical dosage form according to claim 1, wherein the content of the polyalkylene oxide is at least 30 wt.-%, and/or the content of anionic polymer is within the range of 5.0±

4.5 wt.-%, in each case based on the total weight of the pharmaceutical dosage form.

10. The pharmaceutical dosage form according to claim 1, which is thermoformed.

11. The pharmaceutical dosage form according to claim 10, which is hot-melt extruded.

12. The pharmaceutical dosage form according to claim 1, which is tamper-resistant.

13. The pharmaceutical dosage form according to claim 1, wherein the pharmacologically active ingredient is oxycodone or a physiologically acceptable salt thereof.

14. The pharmaceutical dosage form according to claim 1, wherein the opioid antagonist is selected from the group consisting of naltrexone, naloxone, nalmefene, cyclazacine, levallorphan, pharmaceutically acceptable salts thereof and mixtures thereof.

15. The pharmaceutical dosage form according to claim 1, which contains a plasticizer and/or an antioxidant.